Inhibitors of IL-2 production and IL-2 receptor expression in human leukemic T-cell line, Jurkat. 1986

T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita

1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine (H-7), a protein kinase inhibitor, suppressed interleukin 2 (IL-2) production and IL-2 receptor (IL-2R) expression of the human leukemic T-cell line, Jurkat, induced by 12-O-tetradecanoyl-phorbol-13-acetate and phytohemagglutinin-P. This effect was significant at 5 microM H-7 without loss of cell viability. Such activity was not observed with N-(2-guanidinoethyl)-5-isoquinolinesulfonamide (HA 1004), a potent inhibitor of cGMP- and cAMP-dependent kinases, and a weak inhibitor of Ca2+-phospholipid-dependent protein kinase (protein kinase C). These findings suggest that protein kinase C is more closely associated with IL-2 receptor expression and IL-2 production of T cells than cGMP- or cAMP-dependent kinases. In addition, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), a calmodulin inhibitor, suppressed both IL-2 production and IL-2R expression. Cycrosporin A (Cy A), a potent immunosuppressive drug, markedly inhibited IL-2 production of Jurkat cells whereas it did not affect the IL-2R expression. Thus, the mechanism of action of Cy A appears to differ from that of the protein kinase inhibitor, H-7, and the calmodulin inhibitor, W-7.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide

Related Publications

T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
January 2006, Journal of cellular physiology,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
May 1982, European journal of immunology,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
November 1990, Cellular immunology,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
April 2008, Cytokine,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
January 2004, Folia histochemica et cytobiologica,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
March 1988, Journal of leukocyte biology,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
March 1985, Journal of immunology (Baltimore, Md. : 1950),
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
October 2006, Ai zheng = Aizheng = Chinese journal of cancer,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
May 2006, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
T Koizumi, and Y Nakao, and T Matsui, and Y Katakami, and N Katakami, and T Fujita
January 1991, Toxicology and applied pharmacology,
Copied contents to your clipboard!